ArticleCancer immunology, immunotherapy : CII2024

The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.

Yutaka Shimazu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.